Loading viewer...
earnings
Format: PDF earnings
Ascelia Pharma presented its H1 2024 results highlighting the successful completion of Phase 3 clinical development for Orviglance®. The presentation covers quarterly financial performance, recent milestones, and the company's pipeline strategy in orphan oncology focused on delivering targeted cancer treatments.
earnings
22 Pages
Organon
Vertex Pharmaceuticals Q4 2023 Financial Results
earningsearnings
27 Pages
Vertex Pharmaceuticals
International Paper Q3 2023 Earnings Presentation
earningsearnings
34 Pages
International Paper